



International Journal of Biomedical Investigation

Available Online: <http://ijbi.edwiserinternational.com>

Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease

Oldham CE, Powell RS, Williams AB, Dixon S, Wooten CJ, Melendez QM, and Lopez D*

Department of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise [BRITE], College of Arts and Sciences, North Carolina Central University, Durham, USA

Article info

Received 28 February 2018

Revised 20 March 2018

Published 27 March 2018

*Corresponding author: Dr. Lopez D, Department of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise [BRITE], College of Arts and Sciences, North Carolina Central University, Durham, USA; E-mail: lopezd@ncu.edu

Abstract

Alzheimer's disease [AD] is not only the most common neurodegenerative disease but is also currently incurable. Proprotein convertase subtilisin/kexin-9 [PCSK9] is an indirect regulator of plasma low density lipoprotein [LDL] levels controlling LDL receptor expression at the plasma membrane. PCSK9 also appears to regulate the development of glucose intolerance, insulin resistance, abdominal obesity, inflammation, and hypertension, conditions that have been identified as risk factors for AD. PCSK9 levels also depend on age, sex, and ethnic background, factors associated with AD. Herein, we will review indirect evidence that suggests a link between PCSK9 levels and AD.

Keywords: Alzheimer's disease; PCSK9; LDL; Metabolic diseases.

Overview

In 2017, about 5.5 million Americans were diagnosed with Alzheimer's disease [AD] [1]. The majority of the AD patients [96%] were 65 years of age or older; only 4% were under the age of 65 [1]. About 47 million people worldwide are presently suffering from AD, a number predicted to triplicate by 2050 [2,2]. Even though all individuals with AD do not share most symptoms, many symptoms are common to all patients [4]. The more typical prime symptom of AD is short-term memory loss [4]. Over time, the person also suffers a deterioration in his/her ability to perform routine tasks, disorientation, personality changes, and inability to learn new information [4]. AD eventually prevents the person from caring for him or herself [4]. As AD progresses, other symptoms arise such as language impairment, difficulties completing complex tasks, depression, psychotic episodes, and behavioral changes [4,5]. Even with aggressive management, AD patients often live out their final months or years in a vegetative state [6]. Currently, the disease is incurable and fatal [6].

Risk factors for AD are age, familial aggregation of AD, Down's syndrome, and Parkinson's disease, late maternal age, inflammation, head trauma, and family history of dementia, depression, and hypothyroidism [7]. The incidence of AD increases with age, which seems to be the leading cause of AD, and is doubled every five to ten years [7,8]. Genetic mutations are additional contributing factor [7]. Mutations in specific genes lead to increased risk of AD development [9]. Genes with reported connections to AD development include amyloid precursor protein [APP], apolipoprotein [Apo] E4, and Tau [9-13].

Gender is another known risk factor for AD [14]. It has been shown that women acquire AD at a higher rate than men [14,15]. Ethnicity is another crucial determinant of AD [1]. Statistics reveal that African-American are more likely to get AD than Caucasian-Americans [1,16]. Hispanics are statistically the second prevalent ethnic group diagnosed with AD [2,17]. Health disparities such as diabetes, hypertension, and heart diseases are the main reasons for the ethnic differences

in the risk of developing AD [8,18,19]. It has also been shown that exposure to discrimination or poverty and not finishing school are also risk factors for AD [8,18,19].

Development of AD

The distinguishing “hallmark” lesions found in the brain of AD patients are extracellular amyloid β ($A\beta$) plaques (senile plaques) and intracellular neurofibrillary tangles (NFTs) of hyperphosphorylated Tau (Figure 1) [2,17,20]. No new lesions associated with AD brains have been identified since Dr. Alois Alzheimer discovered and described the disease in 1906 [21].

One of the well-publicized proteins related to AD lesions is APP [20]. APP is part of a highly conserved family of type-I transmembrane proteins [10]. This protein is responsible for neuron outgrowth and survival [10]. The precursor protein is oriented with the N-terminal region towards the extracellular space of the cell and the C-terminal domain within the cytosol [10]. APP is cleaved into two different secreted proteins, $A\beta$ or p3 [3-kD soluble peptide], depending on the enzymes available for the processing of APP [22,23]. The normal processing of APP begins with α -secretase that cuts in the middle of the $A\beta$ sequence (Figure 2) [22,23]. The ectodomain- α [ectodomain+N-terminal region of $A\beta$] is released to the extracellular space while γ -secretase cuts the remaining transmembrane domain producing the secreted p3 fragment and the APP intracellular domain (AID) [22,23]. The function of p3 is currently unknown [24]. The AID has been implicated in nuclear signalling [25,26].

$A\beta$ is a short peptide of 39-43 amino acids that could assemble into amyloid or senile plaques in response to abnormal processing of APP [22,23]. The abnormal processing occurs when APP is cleaved first by β -secretase (Figure 2) [22,23]. This cut releases the ectodomain of APP while γ -secretase cleave off the $A\beta$ fragment from the AID [27]. $A\beta$ is then secreted into the extracellular space of the cell where it is assembled into oligomers, which are mostly soluble [28,29]. However, at a high concentration, the conformation of the $A\beta$ oligomers can change into a β -sheet-rich tertiary structure that accumulates forming amyloid plaques around the neurons [28,29]. Highly aggregated $A\beta$ oligomers can form complexes with plasma membrane lipids that leads to membrane disruption, pore formation, and cellular damage [30].

Tau is another crucial gene involved in the development of AD [13]. Tau is a microtubule-associated protein [MAP] mainly expressed in axons of developing and mature neurons and is crucial for

neuronal function [13,31]. The primary function of tau, when phosphorylated, is to bind to microtubules (MTs) and to promote MT stabilization and polymerization [13,31,32]. Tau also stimulates neurite outgrowth, organizes axonal MTs, and is involved in kinesin-dependent axonal transport [32].




Figure 1: Schematic comparing neurons from a healthy and Alzheimer's disease (AD) brain. (A) Structure of neurons from a healthy brain. Typical structural parts of neuronal cells containing myelin are indicated. (B) “Hallmark” lesions of AD. Senile plaques are usually found extracellularly whereas neurofibrillary tangles are found intracellularly.




Figure 2: Pathways for the processing of amyloid precursor protein (APP). (A) Normal pathway involving α and γ secretases and resulting in the formation of p3. (B) Abnormal pathway involving β - and γ - secretases and resulting in the formation of amyloid β ($A\beta$). AID refers to APP intracellular domain.

Tau has three main protein domains, the acidic N-terminal region, a proline-rich middle region [hinge], and a basic C-terminal region [13,31]. The N-terminal region of tau interacts with the plasma membrane

protein dynactin and with the tyrosine kinase Fyn [13,31]. The hinge region of tau influences MT spacing and inhibits kinesin-dependent axonal transport [13,31]. The C-terminal domain contains either three or four MT-binding motifs [changing tau affinity for the MTs] depending on splicing of exon 10 [31,33,34].

Tau undergoes phosphorylation at as many as eighty serine/threonine residues and five tyrosine residues [31]. Tau is crucial for establishing neuronal cell polarity and axonal outgrowth during development, and for maintaining axonal morphology and transport in mature cells [35]. Tau carries out those functions by binding directly to MTs and controlling the MT's growing and shortening dynamics [35]. Previous studies have shown that proper regulation of the MT's dynamics is imperative for cell viability. Tau activity is regulated through two mechanisms, alternative splicing, and phosphorylation [Figure 3] [35,36].

The human tau is composed of 16 exons, three of which, 2, 3, and 10, are alternatively spliced to form six Tau isoforms [37]. Exon 10 encodes the second of four imperfect MT-binding repeats in the C-terminal region of the tau protein [37]. Tau isoforms not including exon 10 have three MT binding domains (3R), whereas tau isoforms including exon 10 have four MT-binding domains (4R) [37,38]. Equal quantities of Tau 3R and Tau 4R [1:1] are expressed in adult human brain [37]. Changes in the ratio of Tau 4R to Tau 3R in the human brain have been associated with the development of neurodegenerative diseases [37]. For example, increases in the Tau 3R isoforms are associated with AD, progressive supranuclear palsy, and cortico basal degeneration [37]. Increases in Tau 4R isoforms have related to fronto temporal dementia and Pick's disease [37].

Sometimes changes in the ratio of Tau 3R and 4R do not indicate a pathological condition. For example, increases in Tau 4R are seen during neurite outgrowth, neuronal differentiation, and cell death [33]. Increases in Tau 3R, however, have been associated with neuronal proliferation and survival [33]. Tau 4R has three times more MT-stabilizing ability than Tau 3R due to the presence of the additional motif [39]. Tau 3R has been shown to inhibit Tau 4R-dependent MT assembly [33]. Thus, an equimolar ratio of Tau 4R and Tau 3R is necessary to maintain proper neuronal microtubule dynamics and to prevent abnormal filament assembly [33,39]. Changes in the ratio of Tau 4R and Tau 3R do not affect the overall levels of tau protein expression [33,39].

Tau phosphorylation is also regulated and can result in a decreased affinity of tau for the MTs [31]. Hyperphosphorylation of Tau is the primary factor involved in the formation of NFTs which trigger disintegration of MTs leading to AD [31]. NFTs are insoluble tau aggregates located within the neurons of AD patients [31]. NFTs mainly affect the cognitive [empathy, affect, social, behavior, language use, and comprehension] of the frontal and temporal cortex [31,40]. Interestingly, several studies suggest that high levels of A β enhance tau phosphorylation leading to the destabilization of microtubules, impaired axonal transport, and death of neurons [41-43]. Therefore, the appearance of A β plaques accentuates the development of NFTs.




Figure 3: Proper processing of Tau and alterations in this processing leading to Alzheimer's disease.

Cholesterol

Cholesterol is a sterol compound found in most body tissues, including blood and the nervous system [44,45]. Cholesterol and its derivatives are essential ingredients of cell membranes and precursors to other steroid compounds such as bile acids, vitamin D, glucocorticoid, estrogen, progesterone, androgen and more [44,45]. However, high concentrations of cholesterol in the bloodstream promote different atherosclerotic-related diseases including heart diseases and strokes [46]. The highest amount of cellular cholesterol [about 30-50%] is found in the plasma membrane where it regulates membrane fluidity [47]. Membranes with a high content of cholesterol have a decreased fluidity, whereas membranes with low content of cholesterol have an increased fluidity [47]. Membrane fluidity is involved in different processes including signal transduction and the transport of nutrients/waste products in and out of the cell [48]. Surprisingly, the brain contains the highest amount of free cholesterol [about 25%] compared to other organs in the human body [49].

The cholesterol found in the bloodstream comes from two primary sources: de novo synthesis and the diet [50,51]. Independently of the source, serum cholesterol is lipoproteins [51,52]. Once dietary cholesterol and other lipids reach the small intestine, they are absorbed by the enterocytes and then packaged with Apo B-48 into nascent chylomicrons [54]. The enzyme responsible for the assembling of nascent chylomicrons within the enterocytes is the microsomal triglyceride (TG) transfer protein (MTP) [54]. Nascent chylomicrons are transported along the secretory pathway, where they acquire Apo E and Apo C-II by exchanging components with the high-density lipoprotein (HDL) particle, followed by secretion of the now mature chylomicrons into the lymph [54]. During their journey through the lymph, TGs contained within chylomicrons are hydrolyzed to supply fatty acids and glycerol to myocytes, adipocytes, and lactating breast tissue, leaving behind TG-depleted chylomicron remnants [54]. Hepatocytes remove chylomicron remnants from the circulation through a process mediated by the low-density lipoprotein (LDL) receptor [54]. The transport of dietary lipids through the circulation is known as the exogenous lipoprotein pathway [54].

In contrast to the exogenous pathway, the endogenous lipoprotein pathway originates in the hepatocytes [51]. Hepatic lipids, including cholesterol, are packaged into Apo B-100/Apo E-containing lipoproteins known as very low-density lipoproteins (VLDL) [55,56]. The assembling of VLDL requires the action of the MTP expressed in hepatocytes [55,56]. Upon secretion, most of the VLDL particles are quickly internalized by the action of the LDL receptor [55,56]. Those VLDL particles that escape the receptor enter the circulation [55, 56]. As for chylomicrons, VLDL acquires Apo C-II in the circulation by exchanging components with the high-density lipoprotein (HDL) [55,56]. Apo C-II allows the hydrolysis of the VLDL's TGs to provide fatty acids to muscle, adipose tissue and lactating breast. The enzyme responsible for hydrolyzing TGs from either chylomicrons or VLDL particles is lipoprotein lipase (LPL), which is activated by Apo C-II [55,56]. The hydrolysis of VLDL's TGs yields intermediate-density lipoprotein (IDL), which is also called β -VLDL or VLDL remnants. IDLs have a high affinity for the LDL receptor and are rapidly taken up by the liver. Those IDL particles that survive the receptor's internalization pathway go on to suffer further hydrolysis [55,56]. Apo E, Apo C-II, and other apolipoproteins present in IDL, except ApoB-100, are transferred back to HDL [55,56]. This process leads to the formation of LDL, which is also removed by the

LDL receptor pathway, but at a reduced rate, when compared to the removal rate of IDL [55,56].

Therefore, the LDL receptor pathway is responsible for the uptake and degradation of most Apo B-containing lipoproteins of the exogenous and endogenous lipoprotein pathways [57,58]. These lipoproteins are chylomicron remnants, VLDL, and IDL, via their Apo E, and LDL, via Apo B-100 [57,58]. About 70% of the cholesterol present in the bloodstream is found in the form of LDL [59,60]. The hepatic LDL receptor is the determining factor of plasma LDL levels [57].

Cholesterol synthesis and transport in different organs

In most organs and under healthy conditions, there is a balance between de novo cholesterol synthesis and its transport in and out of the cell [61,62]. This balance is critical to prevent an over-accumulation of cholesterol within tissues [61,62]. As mentioned above, the liver is the organ responsible for the synthesis of VLDL, which transport triglycerides and cholesterol to most peripheral tissues [51,55,56]. Many of these tissues also synthesize their own cholesterol, some of which is added to LDL [61]. Several organs also transport excess cholesterol to HDL, a process that is mediated by the transporter ABCA1 [61,63]. The cholesterol added to HDL is esterified and transported to the liver where the cholesterol is selectively transported into cells via the scavenger receptor class B type 1 [SR-B1] [63,64]. A significant portion of the cholesterol reaching the liver is secreted from the body either as bile acids or as free cholesterol after secretion into the bile by the action of the transporters ABCG5/8, ABCB4, and ABCB11 [63,65].

It has been proposed by many scientists that the brain has the capacity of acquiring cholesterol either by uptake of plasma lipoproteins across the blood-brain barrier or by de novo synthesis within the neurons [61,66]. In fact, high expression levels of the LDL receptor, SR-B1 and ABCA1 have been detected in brain endothelial cells [67,68]. However, several animal studies have failed to demonstrate that lipoproteins are taken up by brain cells [69-72]. Thus, it appears that the brain makes the majority of its cholesterol, and if this organ takes any lipoproteins from the blood to supplement its cholesterol pool, this contribution is undetectable by the methods utilized in those studies [69-72].

Cholesterol role in myelin formation

The axons of some nerve cells are covered by myelin, which serves as an electrical isolator [73]. The myelin

layer is essential for the functioning of the nervous system since it speeds up the signal transfer process [73]. Loss of the myelin layer either induced in animal studies or due to disease in humans leads to disruption of the signal between neuronal cells [74-77]. Although it could have different chemical components, cholesterol has been identified as an essential constituent of myelin conforming 70-85% of the myelin together with galactocerebroside [78-80]. Other components of myelin are water [40%] and myelin-specific proteins [15-30%] [78-80]. Myelin is what gives the color to the "white matter" of the brain [73].

Myelin is made of two different types of cells. In the central nervous system [CNS; the brain and spinal cord], oligodendrocytes create the myelin sheath after wrapping themselves around the axons of the neuronal cells [81]. In other parts of the nervous system, the myelin is produced by Schwann cells [Figure 1] [81]. In both cases, the function of myelin is the same.

In addition to being part of myelin, cholesterol also plays crucial roles in the synapse, dendrite formation, and axonal guidance [82-84]. Several oxidized products of cholesterol made within the brain influence critical cell functions such as regulation of cholesterol excess within this organ [66,85]. Depleting cholesterol in neurons impairs synaptic vesicle exocytosis, neuronal activity, and neurotransmission, and leads to dendritic spine and synapse degeneration [86,87]. Also, defects in cholesterol metabolism cause structural and functional CNS diseases such as Smith-Lemli-Opitz syndrome, Niemann-Pick C disease, Huntington's disease, Parkinson's disease, and Alzheimer's disease [88-91].

It is critical to discuss that in the brain, the cholesterol pathway and the prenylation of proteins are reciprocally regulated in correlation with the synthesis of A β [92]. In fact, it has been shown that A β inhibits cholesterol synthesis and protein prenylation in neuronal cells [93]. Prenylation is mainly affected due to a lack of isoprenoid from the cholesterol biosynthetic pathway, whereas cholesterol synthesis is reduced as a result of a down-regulation in sterol regulatory element binding protein-2 [SREBP-2] cleavage [93,94].

The LDL receptor gene and its family of proteins

The LDL receptor is a transmembrane glycoprotein found on the surface of cells [58,95]. As described above, this receptor plays a significant role in the removal of cholesterol-carrying Apo B-lipoproteins from the circulation [57,58]. The human LDL receptor gene, which is located on chromosome 19p 13.1-13.3, is approximately 45 kb long [96]. The LDL receptor gene is composed of 18 exons and 17 introns [96]. The

promoter of the LDL receptor gene has two TATA-like sequences and three 16 bp direct repeats critical for the transcription of this gene [97]. Repeats 1 and 3 are recognized by the transcription factor Sp1 and help in maintaining basal LDL receptor transcription levels [97,98]. Repeat 2 is a sterol regulatory element that controls transcription of the LDL receptor in response to sterol levels [99].

The LDL receptor superfamily of proteins also includes the LDL receptor-related protein 1 (LRP1; also known as Apo E receptor or ApoER), LRP1b, ApoER2, LRP4, VLDL receptor, and megalin [99]. In addition to internalizing different lipoproteins, the LDL receptor seems to play a crucial role in preventing A β aggregation and enhancing A β clearance from the extracellular space of the brain [100]. ApoER is involved in intracellular signaling, lipid homeostasis, coagulation, tumor invasion, and clearance of apoptotic cells [102,103]. ApoER is also involved in the metabolism of Apo E within the brain and synapsis [104,105]. LRP1b is critical for normal cell function and development, and in brain cells, it increases expression and normal [α -secretase] cleavage of AP Producing A β production [106,107]. ApoER2 mediates signal transduction, endocytosis of specific ligands, embryonic neuronal migration, and postnatal long-term potentiation [99,108]. This receptor also protects against neuronal cell loss during normal aging [109]. LRP4 is a critical regulator of Wnt signaling and controls synaptic transmission and postsynaptic integration that contribute to long-term plasticity, learning, and memory [110,111]. The VLDL receptor is vital in providing cholesterol to the brain, but it is also essential for tumor growth and neuronal migration in developing brain [99,112, 113]. Like other members of the superfamily, Megalin mediates endocytosis of ligands leading to their degradation in the lysosomes, but it also forms the Heymann nephritis antigenic complex and serves as a receptor for thyroglobulin [114]. In the brain, megalin is involved in A β -mediated neurotoxicity and in the neurodegenerative processes that occur in AD [115]. Many of these receptors directly interact with APP in brain cells controlling the trafficking, processing, and elimination of APP, and consequently, the formation of A β [116]. All these receptors share similarities in their protein structures and ligand internalization pathways [99].

Structure and cycling of the LDL receptor protein

The 18 exons of the LDL receptor gene code for an 839 amino acids protein divided into five functionally distinct domains [58,117]. First, it is the ligand binding domain located at the N-terminal (292 amino acids).

This domain is composed of seven adjacent LDL receptor type-A (LA) modules or repeats (each 40 amino acids long) [58,117]. Each LA repeat uses three conserved calcium atom-binding acidic residues for protein-protein interactions [118]. Immediately next is the epidermal growth factor (EGF) precursor domain (400 amino acids). The EGF precursor domain is composed of two EGF modules or repeats (40 amino acids each), the YWTD region (280 amino acids; contains six YWTD repeats), and a third EGF module (40 amino acids) [58,117]. The YWTD region forms the six-bladed β -propeller that is implicated in the release of bound lipoproteins at low pH [118,119]. The O-linked glycosylation domain (58 amino acids) follows which is rich in serine and threonine residues that get glycosylated [120]. This region does not appear to be involved in ligand binding, internalization, and receptor recycling [120]. The following domain is the transmembrane domain (22 amino acids) that anchors the receptor to the plasma membrane [121]. The last domain is the 50-residue cytoplasmic tail (50 amino acids). The cytoplasmic tail is essential for localization within clathrin-coated pits and receptor endocytosis [122]. After its synthesis within the endoplasmic reticulum, the molecular weight of the LDL receptor is 120 kDa [95]. Upon transport through the Golgi, the LDL receptor undergoes extensive O-linked glycosylation resulting in the mature 160 kDa form found at the cell surface [95].

The LDL receptor removes lipo proteins from the circulation through a process that involves endocytosis of the lipoprotein/LDL receptor complex within clathrin-coated regions [58]. At the plasma membrane, the LDL receptor's extracellular domain is extended, exposing the ligand-binding domain [open position], which allows the lipoprotein binding [118]. The cytosolic domain of the LDL receptor contains an 823FDNPVY sequence that is necessary and sufficient for rapid clathrin-mediated endocytosis [123]. Internalization of the lipoprotein/LDL receptor complex into hepatic cells is controlled mainly by the LDL receptor adaptor protein-1 [124].

After endocytosis, the LDL receptor/lipoprotein complex is delivered to the endosome [118]. Acidification of the endosome occurs facilitating folding of the LDL receptor into the closed position releasing the lipoprotein particle [58,125]. The lipoprotein particle moves to the lysosome, where the cholesteryl esters are hydrolyzed to form free cholesterol and fatty acids, and the protein fraction of the lipoprotein is degraded into free amino acids [58].

Most receptor molecules are recycled back to the cell surface, where they can bind and internalize lipoprotein again [126]. At every round of the cycle, only a minuscule percentage of LDL receptor molecules are degraded [126]. Each LDL receptor molecule completes about 150 cycles before it is finally degraded in about 20 hours [126].

Role of Apo E in the brain

ApoE is a ligand for all members of the LDL receptor family of proteins [112]. This apolipoprotein is also found in many of the lipoprotein particles that transport lipids and cholesterol in the bloodstream [112]. In the nervous system, Apo E is produced by astroglia and microglia cells, whereas neuron cells express the receptors to uptake ApoE [112]. There are three main types of Apo E in humans, E2, E3, and E4 [112]. The main difference between these Apo E isoforms is in two amino acids, specifically residues 112 and 158 [112]. ApoE3 has a cysteine at position 112 and an arginine at position 158; ApoE4 has arginines at both sites, whereas ApoE2 has cysteines at both sites [112]. Having different residues at positions 112 and 158 affects the risk of patients to acquire some diseases [112]. For example, patients that are carriers of the Apo E4 isoform have a higher chance of developing coronary artery disease and AD than patients with the other two isoforms [127]. Inheritance of the ApoE4 allele is the most influentially known genetic risk factor that leads to the development of AD [9].

It currently unknown how having Apo E4, and not Apo E2 or E3, affect a patient's risk to develop these diseases. However, it has been proposed that it is due to the Apo E role in cholesterol transport and brain function [112]. The functions of Apo E in the brain are neuronal survival, synapse formation and plasticity, modulation of neurite outgrowth, destabilization of microtubules, A β clearance, and prevention of NTF formation [112,128-132]. ApoE2 and ApoE3 usually induce neurite outgrowth, whereas ApoE4 inhibits it [112,130,131]. The genotype of Apo E also influences the appearance of neuroinflammation, which has been considered as a potential early indicator of AD risk in humans [133].

Related to the formation of senile plaques, ApoE binds A β and contributes to its clearance and degradation in a process that requires lipoprotein receptors [134-137]. Apo E4 not only enhances the formation of senile plaques but also leads to hypercholesterolemia; Apo E2 is protective against both effects [11,138,139]. The effect of Apo E4 on cholesterol levels also contributes to enhancing the accumulation of A β plaques by

promoting the cleavage of APP through the abnormal pathway [140].

Proprotein convertase subtilisin-kexin type 9 [PCSK9]

PCSK9 was discovered in 2003 when gain-of-function [GOF] mutations in this gene were identified as causative of familial hypercholesterolemia [FH] in an autosomal dominant manner [141]. Serum PCSK9 levels are identified as a key cause of atherosclerosis independently of other risk factors in patients without symptoms [142]. Interestingly, loss-of-function [LOF] mutations of PCSK9 have also been identified and are associated with hypocholesterolemia and substantial protection against cardiovascular diseases [143,144]. PCSK9 is expressed and secreted by multiple tissues but primarily by the liver, small intestines, and kidneys [145]. PCSK9 can also be found in cerebrospinal fluid [CSF] [146] and at the sites of atherosclerotic plaques [147]. There is a definite correlation between wild-type PCSK9 levels and atherogenic lipoproteins such as large VLDL, IDL, the smallest LDL, the smallest HDL, and all remnant lipoproteins [148,149].

Structure and processing of PCSK9

The human PCSK9 gene is localized on chromosome 1p32.3 [150]. This gene is about 22-kb long and comprises 12 exons encoding a 692-amino acid glycoprotein [151]. The protein domains that comprise PCSK9 are a signal peptide, the propeptide or inhibitory prodomain, the subtilisin-like catalytic domain, a hinge region, and a cysteine-rich, histidine-rich, C-terminal domain [152,153].

PCSK9 is synthesized as a 74 kDa precursor protein that undergoes autocatalytic processing in the endoplasmic reticulum to release the propeptide (14 kDa) from the N-terminal region resulting in a processed protein of about 60 kDa [154,155]. This autocleavage is necessary to activate the convertase and to allow its departure from the endoplasmic reticulum [155,156]. After self-cleavage, the prodomain remains in the catalytic groove and obstructs the access of other proteins and peptides [157]. Then, the PCSK9/prodomain complex departs from the endoplasmic reticulum and migrates through the secretory pathway until it is secreted into the bloodstream [154,155].

The main function of PCSK9

The primary function of PCSK9 is to control serum LDL levels by promoting the degradation of the LDL receptor, especially in the liver [158,159]. The GOF mutations of PCSK9 are connected with decreased expression of LDL receptors and internalization of

LDL, while the LOF mutations are associated with increased LDL receptor levels and internalization of LDL [158, 159]. After secretion into the serum, PCSK9 interacts with the EGF-A domain of the LDL receptor at the surface of cells [160,161]. Then, the PCSK9/LDL receptor complex enters the endosomal pathway [160]. Unlike the interaction between lipoprotein and receptor, the affinity of PCSK9 for the LDL receptor at the acidic pH of the endosome is increased over the affinity at the neutral pH [153,162]. PCSK9 helps to keep the LDL receptor in the open conformation preventing its recycling to the plasma membrane causing receptor degradation in the lysosome [163,164].

Other functions of PCSK9

In addition to the LDL receptor, PCSK9 also degrades the VLDL receptor, ApoER, ApoER2, the cluster of differentiation 36 [CD36], β -secretase 1 [BACE1], the epithelial sodium [NA⁺] channel [ENaC], and CD81 [165-171]. Due to the vast number of targets, it is expected that PCSK9 controls multiple pathways. The ENaC, for example, regulates blood pressure by modulating epithelial sodium reabsorption, and PCSK9 regulates the levels of ENaC protein expression suggesting that this convertase also has a role in blood pressure [169]. Furthermore, some rare variants in PCSK9 have been shown to influence blood pressure among African Americans [172]. Recent reports on several ethnic populations have also revealed that blood pressure is positively correlated with circulating PCSK9 levels [173-175].

PCSK9 also affects triglyceride metabolism and accumulation in visceral adipocyte tissue, and these effects are connected to the effects of this convertase on CD36 and the VLDL receptor [176]. In humans, circulating PCSK9 has been shown to be positively associated with body mass index [BMI] [173,175]. Accordingly, exercising, which is essential to regulate body weight and modulating lipid metabolism, reduces the hepatic expression and plasma concentration of PCSK9 [177,178].

PCSK9 is critical during inflammation and for the formation of atherosclerotic plaques [179,180]. Also, PCSK9 levels increase every time there is inflammation in the body [181,182]. Related to thrombosis, it has been reported that the levels of PCSK9 in the plasma are positively and strongly correlated with platelet, white blood cell count, and fibrinogen levels [183,184]. Additionally, circulating PCSK9 positively correlates with high sensitivity C-reactive protein levels [184,185]. Receptors modulated by PCSK9 that are

associated with these processed are the LDL receptor and ApoER2.

Diabetes is a metabolic disturbance that is conditioned to the levels of PCSK9. Although high circulating PCSK9 levels are positively correlated with fasting blood glucose levels and insulin resistance [173,175], having low levels of PCSK9 can also lead to diabetes. Treatment with PCSK9 inhibitors, in addition to statins, results in a cholesterol accumulation in pancreatic islets that causes diabetes [186]. In fact, diabetes is reported in 1.8% of patients that had no diabetes before starting treatment with PCSK9 inhibitors [187,188]. Other side-effects observed when using PCSK9 inhibitors are neurocognitive events, gastrointestinal disturbances, infections, and ophthalmologic events, all related to the roles attributed to PCSK9 based on the receptors that interact with this convertase [189,190].

Hormonal regulation of PCSK9

A hormone that controls the expression of PCSK9 is estrogen [191,192]. Estrogen levels are inversely correlated to circulating PCSK9 in pre-menopausal females [191,192]. Post-menopausal females have 22% more PCSK9 than pre-menopausal females [174,191]. Interestingly, females have 10% more circulating PCSK9 than males suggesting that the inverted relationship between estrogen and PCSK9 levels only applies to females [191,192]. Testosterone, on the other side, does not affect the levels of circulating PCSK9, so it is not involved in the differences in PCSK9 levels between males and females [192]. The hormone that appears to be responsible for these gender differences is growth hormone (GH) [193]. GH is also responsible for the diurnal variation of PCSK9 levels that mimics the diurnal variation of cholesterol synthesis [193].

Insulin and glucagon also regulate the PCSK9 expression [194,195]. It has been found that glucagon downregulates while insulin upregulates the expression of PCSK9 in several animal models [195-197]. Similar decreases in PCSK9 protein expression are seen in intestinal cells from Psammomys obesus with type 2 diabetes [198] and women with gestational diabetes [199]. Thyroid hormone is another hormone that regulates the expression of PCSK9 [200,201]. Thyroid hormone reduces circulating PCSK9 thereby explaining the lower plasma LDL levels seen in hyperthyroidism and the higher LDL levels characteristic of hypothyroidism [200]. In euthyroid subjects, the levels of circulating PCSK9 are positively associated with thyrotropin [TSH] [202]. Serum PCSK9 concentrations significantly increase with age, especially in females [173,203]. Interestingly, adiposity can interfere with

this relationship between PCSK9 and TSH [202], which might be related to the positive correlation between BMI and PCSK9 levels overcoming the effects of thyroid hormone [203].

Potential Link between PCSK9 and AD

Age and gender are risk factors for the development of AD, and in both cases, PCSK9 seems to be the connecting factor. Thyroid hormone, which appears to be responsible for the increase in PCSK9 levels as people age [173], also controls the expression of APP and the splicing of tau exon 10 [34,36,204,205]. Thyroid hormone decreases the expression of APP which in turns results in a reduction in A β levels [204,205]. Changes in the splicing of tau exon 10 are known to cause AD [206].

Females suffer from hypothyroidism at a higher rate [4:1] than males [207] and also have consistently higher levels of PCSK9 than men [191,192]. Therefore, it appears that females suffer from AD more than males because of their higher levels of PCSK9 in correlation with lower levels of thyroid hormones. Some researchers have indicated that the differences in females versus males on AD risk are related to the protection that estrogens provide to the mitochondria against A β -toxicity preventing apoptosis of neuronal cells, and it is lost once females enter menopause [14]. However, the possibility that the age-dependent increase in PCSK9 levels, due to a decrease in both thyroid hormone and estrogen, is what enhances neuron apoptosis cannot be discarded [179]. In fact, PCSK9 is well-known to cause apoptosis in neurons, an effect that is mediated by the ApoER2 and VLDL receptors [179].

In mice, upregulation of PCSK9 is seen in response to cerebral ischemia [179,208] and whenever signs of neuronal apoptosis are seen [209]. Interestingly, it has been shown that PCSK9 is necessary for brain development, especially in the cerebellum [210], so inhibiting PCSK9 may cause problems with this function. It is important to mention that any involvement of PCSK9 on AD is questionable since PCSK9 degrades BACE1, which could prevent the formation of A β peptides [168]. Interestingly, one of the side effects of using PCSK9 inhibitors is an increase in neurocognitive events correlating with an adverse effect of low levels of PCSK9 in the brain [191,192].

Another important consideration is that by degrading the LDL receptor, ApoER, and ApoER2, elevated levels of PCSK9 may also help in the development of AD due to an increase in the formation of A β plaques [100,104,109]. Inhibiting ApoER2 could also lead to neuronal cell apoptosis [109]. Thus, variations in the

normal levels, either up or down, of PCSK9 could lead to AD. PCSK9 is detected in CSF [146] indicating that this convertase could directly affect the expression of those receptors in the brain.

The development of AD also has another major contributor that is often overlooked, cholesterol. High levels of cholesterol in the brain seems to be critical for the development of healthy neurons. Studies have shown that elevated levels of total and LDL cholesterol are associated with higher memory scores for noncarriers of the Apo E4 allele [211].

However, in another study, it was reported that high cholesterol levels could lead to AD [19]. PCSK9 works by increasing LDL concentrations in the serum, so elevated levels of this protease would cause the effects seen in the latter study [19]. Likewise, inhibition of PCSK9 which leads to low LDL levels in correlation with neurocognitive events would agree with the first study [211]. Interestingly, African-Americans, who carry LOF mutations in PCSK9 that are associated with hypocholesterolemia, are at a higher risk of developing AD than Caucasians [212], also in agreement with the first study [211].

Neuronal cells control the amount of intracellular cholesterol by converting excess cholesterol into oxidized products that serve as regulators of cholesterol synthesis, and they can be efficiently secreted out of the cells in a process that involves ABCA1 and HDL [213].

Thus, higher levels of HDL would be of great benefit because this lipoprotein could help reduce cholesterol levels in the brain. Interestingly, PCSK9 inhibition has been associated with slightly higher HDL levels [211], so low concentrations of PCSK9 would prevent neuronal damage due to excess levels of cholesterol.

In addition to the risk factors for AD mentioned above, some researchers have suggested that other factors such as diabetes mellitus, hypertension, obesity, and physical inactivity could be considered as causative of AD [18,214]. Surprisingly, the levels of circulating PCSK9 are positively associated with blood pressure and BMI [173-175], whereas changes in total PCSK9 levels, in either direction, can lead to diabetes [173,175,187,188]. PCSK9 levels also increase in response to inflammation [181,182], which is another risk factor for AD.

Besides, physical inactivity has been shown to lead to higher levels of PCSK9 [177,178], which could also explain that this is a risk factor for AD.

Conclusions

Indirect evidence suggests a connection between PCSK9 levels and AD. Figure 4 summarizes the evidence discussed herein. Variations in PCSK9 levels, either up and down, seems to cause an unbalance in the amount of cholesterol required for the proper functioning of the brain and to prevent the proper processing of APP and removal of A β , a critical component of one of the main lesions found in AD. PCSK9 also appears to work by exacerbating several metabolic conditions that are risk factors for AD. Studies are needed to confirm this link between PCSK9 levels and AD.




Figure 4: Schematic representation of all the factors connecting PCSK9 levels and Alzheimer's disease. Abbreviations: PCSK9, proprotein convertase subtilisin-kexin 9; BACE-1, beta-secretase 1; A β , amyloid beta; LDLR, low density lipoprotein receptor; ApoER, apolipoprotein E receptor.

Acknowledgments

This project was supported by funds from the State of North Carolina and BRITE Institute. The authors would like to acknowledge the support of the Golden LEAF Foundation and Dr. Faye Calhoun.

References

1. Association A.S. Alzheimer's Disease Facts and Figures. In. Alzheimer's Association, www.alz.org. 2017; 13: 325-373.
2. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimers Dement* 2013; 9: 63-75 e62.
3. Reitz, C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. *Nat Rev Neurol* 2011; 7: 137-152.

4. Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. *Cold Spring Harb Perspect Med* 2012; 2: a006148.
5. Neugroschl J, Wang S. Alzheimer's disease: diagnosis and treatment across the spectrum of disease severity. *Mt Sinai J Med* 2011; 78: 596-612.
6. Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. *Dis Mon* 2010; 56: 484-546.
7. Bird TD. Genetic aspects of Alzheimer disease. *Genet Med* 2008; 10: 231-239.
8. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. *Dialogues Clin Neurosci* 2009; 11: 111-128.
9. Bekris LM, Yu CE, Bird TD, et al. Genetics of Alzheimer disease. *J Geriatr Psychiatry Neurol* 2010; 23: 213-227.
10. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. *Annu Rev Neurosci* 2011; 34: 185-204.
11. Liu CC, Liu CC, Kanekiyo T, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat Rev Neurol* 2013; 9: 106-118.
12. Bagyinszky E, Youn YC, An SS, et al. The genetics of Alzheimer's disease. *Clin Interv Aging* 2014; 9: 535-551.
13. Wolfe MS. Tau mutations in neurodegenerative diseases. *The J Bio Chem* 2009; 284: 6021-6025.
14. Vina J, Lloret A. Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. *J Alzheimers Dis* 2010; 20: S527-533.
15. Musicco M. Gender differences in the occurrence of Alzheimer's disease. *Funct Neurol* 2009; 24: 89-92.
16. Barnes LL, Bennett DA. Alzheimer's disease in African Americans: risk factors and challenges for the future. *Health Aff [Millwood]* 2014; 33: 580-586.
17. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. *Cold Spring Harb Perspect Med* 2010; 2: 10.1101/cshperspect. a006239.
18. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol* 2011; 10: 819-828.
19. Sjogren M, Blennow K. The link between cholesterol and Alzheimer's disease. *World J Biol Psychiatry* 2005; 6: 85-97.
20. Cole SL, Vassar R. The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. *The J Bio Chem* 2008; 283: 29621-29625.
21. Tagarelli A, Piro A, Tagarelli G, et al. Alois Alzheimer: a hundred years after the discovery of the eponymous disorder. *Int J Biomed Sci* 2006; 2: 196-204.
22. Chow VW, Mattson MP, Wong PC, et al. An overview of APP processing enzymes and products. *Neuromolecular Med* 2010; 12: 1-12.
23. Haass C, Kaether C, Thinakaran G, et al. Trafficking and proteolytic processing of APP. *Cold Spring Harb Perspect Med* 2012; 2: a006270.
24. Nhan HS, Chiang K, Koo EH. The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes. *Acta Neuropathol* 2015; 129: 1-19.
25. Cao X, Sudhof TC. A transcriptionally [correction of transcriptionally] active complex of APP with Fe65 and histone acetyltransferase Tip60. *Science* 2001; 293: 115-120.
26. von Rotz RC, Kohli BM, Bosset J, et al. The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. *J Cell Sci* 2004; 117: 4435-4448.
27. Pinnix I, Ghiso JA, Pappolla MA, et al. Major carboxyl terminal fragments generated by gamma-secretase processing of the Alzheimer amyloid precursor are 50 and 51 amino acids long. *Am J Geriatr Psychiatry* 2013; 21: 474-483.
28. Mucke L, Selkoe DJ. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. *Cold Spring Harb Perspect Med* 2012; 2: a006338.
29. Walsh DM, Selkoe DJ. A beta oligomers-a decade of discovery. *J Neurochem* 2007; 101: 1172-1184.
30. Rangachari V, Dean DN, Rana P, et al. Cause and consequence of A beta - Lipid interactions in Alzheimer disease pathogenesis. *Biochimica et biophysica acta* 2018.
31. Andreadis A. Tau splicing and the intricacies of dementia. *J Cell Physiol* 2012; 227: 1220-1225.
32. Johnson GV, Stoothoff WH. Tau phosphorylation in neuronal cell function and dysfunction. *J Cell Sci* 2004; 117: 5721-5729.
33. Panda D, Samuel JC, Massie M, et al. Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease. *Proc Natl Acad Sci USA* 2003; 100: 9548-9553.
34. Zhou J, Yu Q, Zou T. Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. *BMC Neurosci* 2008; 9: S10.
35. Feinstein SC, Wilson L. Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. *Biochimica et biophysica acta* 2005; 1739: 268-279.

36. Aniello F, Couchie D, Bridoux AM, et al. Splicing of juvenile and adult tau mRNA variants is regulated by thyroid hormone. *Proceedings of the National Academy of Sciences of the United States of America* 1991; 88: 4035-4039.
37. Connell JW, Rodriguez-Martin T, Gibb GM, et al. Quantitative analysis of tau isoform transcripts in sporadic tauopathies. *Brain Res Mol Brain Res* 2005; 137: 104-109.
38. Zhou J, Yu Q, Zou T. Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. *BMC neuroscience* 2008; 9: S10.
39. Goode BL, Chau M, Denis PE, et al. Structural and functional differences between 3-repeat and 4-repeat tau isoforms. Implications for normal tau function and the onset of neurodegenerative disease. *The J Bio Chem* 2000; 275: 38182-38189.
40. Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer disease. *Cold Spring Harb Perspect Med* 2011; 1: a006189.
41. Calhoun ME, Wiederhold KH, Abramowski D, et al. Neuron loss in APP transgenic mice. *Nature* 2008; 395: 755-756.
42. Gotz J, Chen F, van Dorpe J, et al. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by A β 42 fibrils. *Science* 2001; 293: 1491-1495.
43. Zheng WH, Bastianetto S, Mennicken F, et al. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. *Neuroscience* 2002; 115: 201-211.
44. Maxfield FR, van Meer G. Cholesterol, the central lipid of mammalian cells. *Curr Opin Cell Biol* 2010; 22: 422-429.
45. Ikonen E. Cellular cholesterol trafficking and compartmentalization. *Nat Rev Mol Cell Biol* 2008; 9: 125-138.
46. Rafieian-Kopaei M, Setorki M, Douidi M, et al. Atherosclerosis: process, indicators, risk factors and new hopes. *Int J Prev Med* 2014; 5: 927-946.
47. Yang ST, Kreutzberger AJB, Lee J, et al. The role of cholesterol in membrane fusion. *Chem Phys Lipids* 2016; 199: 136-143.
48. Tillman TS, Cascio M. Effects of membrane lipids on channel structure and function. *Cell Biochem Biophys* 2003; 38: 161-190.
49. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. *Curr Opin Lipidol* 2001; 12: 105-112.
50. Goedeke L, Fernandez-Hernando C. Regulation of cholesterol homeostasis. *Cell Mol Life Sci* 2012; 69: 915-930.
51. Nes WD. Biosynthesis of cholesterol and other sterols. *Chem Rev* 2011; 111: 6423-6451.
52. Daniels TF, Killinger KM, Michal JJ, et al. Lipoproteins, cholesterol homeostasis and cardiac health. *Int J Biol Sci* 2009; 5: 474-488.
53. Zhang H, Temel RE, Martel C. Cholesterol and lipoprotein metabolism: Early Career Committee contribution. *Arterioscler Thromb Vasc Biol* 2014; 34: 1791-1794.
54. Hussain MM. Intestinal lipid absorption and lipoprotein formation. *Curr Opin Lipidol* 2014; 25: 200-206.
55. Adeli K, Taghibiglou C, Van Iderstine SC, et al. Mechanisms of Hepatic Very Low-Density Lipoprotein Overproduction in Insulin Resistance. *Trends in Cardiovascular Medicine* 2011; 11: 170-176.
56. Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. *Arterioscler Thromb Vasc Biol* 2012; 32: 2104-2112.
57. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. *Science* 1986; 232: 34-47.
58. Gent J, Braakman I. Low-density lipoprotein receptor structure and folding. *Cell Mol Life Sci* 2004; 61: 2461-2470.
59. Goldstein JL, Hobbs HH, Brown MS. The metabolic and molecular bases of inherited diseases. In: McGraw-Hill Medical Publishing Division; 8th edn New York 2001; 2863-2913.
60. Innerarity TL, Weisgraber KH, Arnold KS, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. *Proc Natl Acad Sci USA* 1987; 84: 6919-6923.
61. Dietschy JM. Central nervous system: cholesterol turnover, brain development and neurodegeneration. *Biol Chem* 2009; 390: 287-293.
62. Stellaard F, Lutjohann D. The Interpretation of Cholesterol Balance Derived Synthesis Data and Surrogate Noncholesterol Plasma Markers for Cholesterol Synthesis under Lipid Lowering Therapies. *Cholesterol* 2017: 5046294.
63. Tosheska Trajkovska K, Topuzovska S. High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol. *Anatol J Cardiol* 2017; 18: 149-154.
64. Acton S, Rigotti A, Landschulz KT, et al. Identification of scavenger receptor SR-BI as a high-density lipoprotein receptor. *Science* 1996; 271: 518-520.
65. Dietschy JM, Turley SD. Control of cholesterol turnover in the mouse. *The J Bio Chem* 2002; 277: 3801-3804.

66. Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. *Protein Cell* 2015; 6: 254-264.
67. Dehouck B, Fenart L, Dehouck MP, et al. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. *J Cell Biol* 1997; 138: 877-889.
68. Panzenboeck U, Balazs Z, Sovic A, et al. ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. *The J Bio Chem* 2002; 277: 42781-42789.
69. Turley SD, Burns DK, Rosenfeld CR, et al. Brain does not utilize low density lipoprotein-cholesterol during fetal and neonatal development in the sheep. *Journal of Lipid Research* 1996; 37: 1953-1961.
70. Turley SD, Burns DK, Dietschy JM. Preferential utilization of newly synthesized cholesterol for brain growth in neonatal lambs. *Am J Physiol* 1998; 274: E1099-1105.
71. Quan G, Xie C, Dietschy JM, et al. Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. *Brain Res Dev Brain Res* 2003; 146: 87-98.
72. Dietschy JM, Turley SD. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. *J Lipid Res* 2004; 45: 1375-1397.
73. Saher G, Brugger B, Lappe-Siefke C, et al. High cholesterol level is essential for myelin membrane growth. *Nat Neurosci* 2005; 8: 468-475.
74. Kimura M, Inoko H, Katsuki M, et al. Molecular Genetic-Analysis of Myelin-Deficient Mice - Shiverer Mutant Mice Show Deletion in Gene[S] Coding for Myelin Basic-Protein. *Journal of Neurochemistry* 1985; 44: 692-696.
75. Podbielska M, Banik NL, Kurowska E, et al. Myelin recovery in multiple sclerosis: the challenge of remyelination. *Brain Sci* 2013; 3: 1282-1324.
76. Alizadeh A, Dyck SM, Karimi-Abdolrezaee S. Myelin damage and repair in pathologic CNS: challenges and prospects. *Front Mol Neurosci* 2015; 8: 35.
77. Sedel F, Bernard D, Mock DM, et al. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. *Neuropharmacology* 2016; 110: 644-653.
78. O'Brien JS, Sampson EL, Stern MB. Lipid composition of myelin from the peripheral nervous system. Intradural spinal roots. *J Neurochem* 1967; 14: 357-365.
79. Schmitt S, Castelvetti LC, Simons M. Metabolism and functions of lipids in myelin. *Biochimica et biophysica acta* 2015; 1851: 999-1005.
80. Garbay B, Heape AM, Sargueil F, et al. Myelin synthesis in the peripheral nervous system. *Prog Neurobiol* 2000; 61: 267-304.
81. Carmody DP, Dunn SM, Boddie-Willis AS, et al. A quantitative measure of myelination development in infants, using MR images. *Neuroradiology* 2004; 46: 781-786.
82. Goritz C, Mauch DH, Pfrieder FW. Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. *Mol Cell Neurosci* 2005; 29: 190-201.
83. Fester L, Zhou L, Butow A, et al. Cholesterol-promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus. *Hippocampus* 2009; 19: 692-705.
84. de Chaves EI, Rusinol AE, Vance DE, et al. Role of lipoproteins in the delivery of lipids to axons during axonal regeneration. *The J Bio Chem* 1997; 272: 30766-30773.
85. Bjorkhem I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. *J Intern Med* 2006; 260: 493-508.
86. Linetti A, Fratangeli A, Taverna E, et al. Cholesterol reduction impairs exocytosis of synaptic vesicles. *J Cell Sci* 2010; 123: 595-605.
87. Liu Q, Trotter J, Zhang J, M. M. Peters, H. Cheng, J. Bao, X. Han, E. J. Weeber, and G. Buet al. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. *J Neurosci* 2010; 30: 17068-17078.
88. Kanungo S, Soares N, He M, et al. Sterol metabolism disorders and neurodevelopment-an update. *Dev Disabil Res Rev* 2013; 17: 197-210.
89. Madra M, Sturley SL. Niemann-Pick Type C pathogenesis and treatment: from statins to sugars. *Clin Lipidol* 2010; 5: 387-395.
90. Block RC, Dorsey ER, Beck CA, et al. Altered cholesterol and fatty acid metabolism in Huntington disease. *J Clin Lipido* 2010; 14: 17-23.
91. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. *Nat Rev Neurosci* 2011; 12: 284-296.
92. Posse de Chaves E 2012. Reciprocal regulation of cholesterol and beta amyloid at the subcellular level in Alzheimer's disease. *Can J Physiol Pharmacol* 2012; 90: 753-764.

93. Mohamed A, Saavedra L, Di Pardo A, et al. beta-amyloid inhibits protein prenylation and induces cholesterol sequestration by impairing SREBP-2 cleavage. *J Neurosci* 2012; 32: 6490-6500.
94. Mohamed A, Viveiros A, Williams K, et al. Abeta inhibits SREBP-2 activation through Akt inhibition. *J Lipid Res* 2018; 59: 1-13.
95. Beglova, N., and S. C. Blacklow. 2005. The LDL receptor: how acid pulls the trigger. *Trends in biochemical sciences* 30: 309-317.
96. Francke U, Brown MS, Goldstein JL. Assignment of the human gene for the low-density lipoprotein receptor to chromosome 19: synteny of a receptor, a ligand, and a genetic disease. *Proc Natl Acad Sci USA* 1984; 81: 2826-2830.
97. Sudhof TC, Van der Westhuyzen DR, Goldstein JL, et al. Three direct repeats and a TATA-like sequence are required for regulated expression of the human low-density lipoprotein receptor gene. *The J Bio Chem* 1987; 262: 10773-10779.
98. Chang R, Yang E, Chamblis D, et al. In vivo role of the Sp1 site neighboring sterol-responsive element-1 in controlling low-density lipoprotein receptor gene expression. *Biochemical and biophysical research communications* 1996; 218: 733-739.
99. Smith JR, Osborne TF, Goldstein JL, et al. Identification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptor gene. *The J Bio Chem* 1990; 265: 2306-2310.
100. Nykjaer A, Willnow TE. The low-density lipoprotein receptor gene family: a cellular Swiss army knife? *Trends Cell Biol* 2002; 12: 273-280.
101. Kim J, Castellano JM, Jiang H, et al. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. *Neuron* 2009; 64: 632-644.
102. Etique N, Verzeaux L, Dedieu S, et al. LRP-1: a checkpoint for the extracellular matrix proteolysis. *Biomed Res Int* 2013: 152163.
103. Strickland DK, Au DT, Cunfer P. Low-density lipoprotein receptor-related protein-1: role in the regulation of vascular integrity. *Arterioscler Thromb Vasc Biol* 2014; 34: 487-498.
104. Bu G. ApoE and apoE receptors in brain lipid metabolism and AD. *Molecular Neurodegeneration* 2012; 7: L10.
105. Shinohara M, Tachibana M, Kanekiyo T, et al. Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. *J Lipid Res* 2017; 58: 1267-1281.
106. Sonoda I, Imoto I, Inoue J, et al. Frequent silencing of low density lipoprotein receptor-related protein 1B [LRP1B] expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. *Cancer Res* 2004; 64: 3741-3747.
107. Cam JA, Zerbinatti CV, Knisely JM, et al. The low-density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. *The J Biol Chem* 2004; 279: 29639-29646.
108. Lane-Donovan C, Herz J. The ApoE receptors Vldlr and Apoer2 in central nervous system function and disease. *J Lipid Res* 2017; 58: 1036-1043.
109. Beffert U, Nematollah Farsian F, Masiulis I, et al. ApoE receptor 2 controls neuronal survival in the adult brain. *Curr Biol* 2006; 16: 2446-2452.
110. Ohazama A, Johnson EB, Ota MS, et al. Lrp4 modulates extracellular integration of cell signaling pathways in development. *PLoS One* 2008; 3: e4092.
111. Gomez AM, Froemke RC, Burden SJ. 2014. Synaptic plasticity and cognitive function are disrupted in the absence of Lrp4. *Elife* 2014; 3: e04287.
112. Beffert U, Stolt PC, Herz J. Functions of lipoprotein receptors in neurons. *J Lipid Res* 2004; 45: 403-409.
113. Reddy SS, Connor TE, Weeber EJ, et al. Similarities and differences in structure, expression, and functions of VLDLR and ApoER2. *Mol Neurodegener* 2011; 6: 30.
114. Marzolo MP, Farfan P. New Insights into the Roles of Megalin/LRP2 and the Regulation of its Functional Expression. *Biol Res* 2011; 44: 89-105.
115. Alvira-Botero X, Perez-Gonzalez R, Spuch C, et al. Megalin interacts with APP and the intracellular adapter protein FE65 in neurons. *Mol Cell Neurosci* 2010; 45: 306-315.
116. Pohlkamp T, Wasser CR, Herz J. Functional Roles of the Interaction of APP and Lipoprotein Receptors. *Front Mol Neurosci* 2017; 10: 54.
117. Sudhof TC, Goldstein JL, Brown MS, et al. The LDL receptor gene: a mosaic of exons shared with different proteins. *Science* 1985; 228: 815-822.
118. Jeon H, Meng W, Takagi J, et al. Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. *Nature structural biology* 2001; 8: 499-504.
119. Davis CG, Goldstein JL, Sudhof TC, et al. Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. *Nature* 1987; 326: 760-765.

120. Davis, C. G., A. Elhammer, D. W. Russell, W. J. Schneider, S. Kornfeld, M. S. Brown, and J. L. Goldstein. 1986. Deletion of clustered O-linked carbohydrates does not impair function of low density lipoprotein receptor in transfected fibroblasts. *J Bio Chem* 261: 2828-2838.
121. Russell DW, Brown MS, Goldstein JL. Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins. *The J Bio Chem* 1989; 264: 21682-21688.
122. Davis CG, van Driel IR, Russell DW, et al. The low-density lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for rapid endocytosis. *The J Bio Chem* 1987; 262: 4075-4082.
123. Chen WJ, Goldstein JL, Brown MS. NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low-density lipoprotein receptor. *The J Bio Chem* 1990; 265: 3116-3123.
124. He G, Gupta S, Yi M, et al. ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2. *The J Bio Chem* 2002; 277: 44044-44049.
125. Rudenko G, Henry L, Henderson K, et al. Structure of the LDL receptor extracellular domain at endosomal pH. *Science* 2002; 298: 2353-2358.
126. Brown MS, Anderson RG, Goldstein JL. Recycling receptors: the round-trip itinerary of migrant membrane proteins. *Cell* 1983; 32: 663-667.
127. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 1993; 261: 921-923.
128. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. *Neuron* 2009; 63: 287-303.
129. Rohn TT, McCarty KL, Love JE, et al. Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome? *Journal of Parkinson's disease and Alzheimer's disease* 2014; 1: 7.
130. Nathan BP, Chang KC, Bellosta S, et al. The Inhibitory Effect of Apolipoprotein E4 on Neurite Outgrowth Is Associated with Microtubule Depolymerization. *J Bio Chem* 1995; 270: 19791-19799.
131. Nathan BP, Bellosta S, Sanan DA, et al. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. *Science* 1994; 264: 850-852.
132. Huynh TV, Davis AA, Ulrich JD, et al. Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-beta and other amyloidogenic proteins. *J Lipid Res* 2017; 58: 824-836.
133. Rebeck GW. The role of APOE on lipid homeostasis and inflammation in normal brains. *J Lipid Res* 2017; 58: 1493-1499.
134. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends in pharmacological sciences* 1991; 12: 383-388.
135. LaDu MJ, Falduto MT, Manelli AM, et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. *The J Bio Chem* 1994; 269: 23403-23406.
136. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci USA* 1993; 90: 1977-1981.
137. Rebeck GW, Reiter JS, Strickland DK, et al. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. *Neuron* 1993; 11: 575-580.
138. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. *Nature genetics* 1997; 17: 263-264.
139. Bales KR, Verina T, Cummins DJ, et al. Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. *Proceedings of the National Academy of Sciences* 1999; 96: 15233-15238.
140. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. *Proc Natl Acad Sci USA* 1998; 95: 6460-6464.
141. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nature genetics* 2003; 34: 154-156.
142. Chan DC, Pang J, McQuillan BM, et al. Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults. *Heart Lung Circ* 2016; 25: 520-525.
143. Folsom AR, Peacock JM, Boerwinkle E, et al. Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. *Atherosclerosis* 2009; 202: 211-215.
144. Mayne J, Dewpura T, Raymond A, et al. Novel loss-of-function PCSK9 variant is associated with

- low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. *Clinical chemistry* 2011; 57: 1415-1423.
145. Melendez QM, Krishnaji ST, Wooten CJ, et al. Hypercholesterolemia: The role of PCSK9. *Archives of biochemistry and biophysics* 2017; 625-626: 39-53.
146. Chen YQ, Troutt JS, Konrad RJ. PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day. *Lipids* 2014; 49: 445-455.
147. Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 [PCSK9] secreted by cultured smooth muscle cells reduces macrophages LDLR levels. *Atherosclerosis* 2012; 220: 381-386.
148. Araki S, Suga S, Miyake F, et al. Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants. *Early Hum Dev* 2014; 90: 607-611.
149. Lambert G, Petrides F, Chatelais M, et al. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. *J Am Coll Cardiol* 2014; 63: 2365-2373.
150. Hunt SC, Hopkins PN, Bulka K, et al. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. *Arterioscler Thromb Vasc Biol* 2000; 20: 1089-1093.
151. Corral P. Back to basics: PCSK9 as a new target for the LDL receptor. *Arq Bras Cardiol* 2014; 102: e5-8.
152. Hampton EN, Knuth MW, Li J, et al. The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain. *Proc Natl Acad Sci USA* 2007; 104: 14604-14609.
153. Piper DE, Jackson S, Liu Q, et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. *Structure* 2007; 15: 545-552.
154. Grozdanov PN, Petkov PM, Karagyozov LK, et al. Expression and localization of PCSK9 in rat hepatic cells. *Biochemistry and cell biology = Biochimie et biologie cellulaire* 2006; 84: 80-92.
155. Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low-density lipoprotein [LDL] receptor and LDL cholesterol. *The J Bio Chem* 2004; 279: 48865-48875.
156. Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. *Proc Natl Acad Sci USA* 2004; 101: 7100-7105.
157. Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. *Nature structural & molecular biology* 2007; 14: 413-419.
158. Cameron J, Holla OL, Ranheim T, et al. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. *Human molecular genetics* 2006; 15: 1551-1558.
159. Saavedra YG, Day R, Seidah NG. The M2 module of the Cys-His-rich domain [CHRD] of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor [LDLR] degradation pathway. *The J Bio Chem* 2012; 287: 43492-43501.
160. Qian YW, Schmidt RJ, Zhang Y, et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. *J Lipid Res* 2007; 48: 1488-1498.
161. DeVay RM, Yamamoto L, Shelton DL, et al. Common Proprotein Convertase Subtilisin/Kexin Type 9 [PCSK9] Epitopes Mediate Multiple Routes for Internalization and Function. *PLoS One* 2015; 10: e0125127.
162. Lo Surdo P, Bottomley MJ, Calzetta A, et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. *EMBO reports* 2011; 12: 1300-1305.
163. Tveten K, Holla OL, Cameron J, et al. Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification. *Human molecular genetics* 2012; 21: 1402-1409.
164. Yamamoto T, Lu C, Ryan RO. A two-step binding model of PCSK9 interaction with the low-density lipoprotein receptor. *The J Bio Chem* 2011; 286: 5464-5470.
165. Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor [LDLR] and its closest family members VLDLR and ApoER2. *The J Bio Chem* 2008; 283: 2363-2372.
166. Roubtsova A, Chamberland A, Marcinkiewicz J, et al. PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice. *J Lipid Res* 2015; 56: 2133-2142.
167. Demers A, Samami S, Lauzier B, et al. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.

- Arterioscler Thromb Vasc Biol 2015; 35: 2517-2525.
168. Jonas MC, Costantini C, Puglielli L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. *EMBO reports* 2008; 9: 916-922.
169. Sharotri V, Collier DM, Olson DR, et al. Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 [PCSK9]. *J Biol Chem* 2012; 287: 19266-19274.
170. Labonte P, Begley S, Guevin C, et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. *Hepatology* 2009; 50: 17-24.
171. Le QT, Blanchet M, Seidah NG, et al. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 [PCSK9] and Low-Density Lipoprotein Receptor [LDLR], and Its Levels Are Reduced by PCSK9. *J Biol Chem* 2015; 290: 23385-23400.
172. Tran NT, Aslibekyan S, Tiwari HK, et al. PCSK9 variation and association with blood pressure in African Americans: preliminary findings from the HyperGEN and REGARDS studies. *Front Genet* 2015; 6: 136.
173. Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. *The Journal of clinical endocrinology and metabolism* 2009; 94: 2537-2543.
174. Baass, A., G. Dubuc, M. Tremblay, E. E. Delvin, J. O'Loughlin, E. Levy, J. Davignon, and M. Lambert. 2009. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. *Clinical chemistry* 55: 1637-1645.
175. Cui Q, Ju X, Yang T, et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. *Atherosclerosis* 2010; 213: 632-636.
176. Roubtsova A, Munkonda MN, Awan Z, et al. Circulating proprotein convertase subtilisin/kexin 9 [PCSK9] regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. *Arterioscler Thromb Vasc Biol* 2011; 31: 785-791.
177. Ngo Sock ET, Chapados NA, Lavoie JM. LDL receptor and Pcsk9 transcripts are decreased in liver of ovariectomized rats: effects of exercise training. *Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme* 2014; 46: 550-555.
178. Kamani CH, Gencer B, Montecucco F, et al. Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population. *Eur J Clin Invest* 2015; 45: 1017-1024.
179. Kysenius K, Muggalla P, Matlik K, et al. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. *Cell Mol Life Sci* 2012; 69: 1903-1916.
180. Giunzioni I, Tavori H, Covarrubias R, et al. Local effects of human PCSK9 on the atherosclerotic lesion. *J Pathol* 2016; 238: 52-62.
181. Ruscica M, Ricci C, Macchi C, et al. Suppressor of Cytokine Signaling-3 [SOCS-3] Induces Proprotein Convertase Subtilisin Kexin Type 9 [PCSK9] Expression in Hepatic HepG2 Cell Line. *J Biol Chem* 2016; 291: 3508-3519.
182. Miyazawa H, Honda T, Miyauchi S, et al. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration. *Clinica Chimica Acta* 2012; 413: 154-159.
183. Li S, Guo YL, Xu RX, et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. *Atherosclerosis* 2014; 234: 441-445.
184. Zhang Y, Zhu CG, Xu RX, et al. Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. *J Clin Lipidol* 2014; 8: 494-500.
185. Li JJ, Li S, Zhang Y, et al. Proprotein Convertase Subtilisin/Kexin type 9, C-Reactive Protein, Coronary Severity, and Outcomes in Patients with Stable Coronary Artery Disease: A Prospective Observational Cohort Study. *Medicine [Baltimore]* 2015; 94: e2426.
186. Marais AD, Kim JB, Wasserman SM, et al. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. *Pharmacol Ther* 2015; 145: 58-66.
187. Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. *BMC Med* 2015; 13: 123.
188. Devito F, Zito A, Ricci G, R. et al. Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia. *Pharmacol Res* 2015; 102: 168-175.
189. Yoon CH, Watson K. Biologics for the treatment of dyslipidemias: a look beyond conventional therapy. *The Annals of pharmacotherapy* 2014; 48: 238-249.
190. Giugliano RP, Sabatine MS. Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? *J Am Coll Cardiol* 2015; 65: 2638-2651.

191. Ghosh M, Galman C, Rudling M, et al. Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. *J Lipid Res* 2015; 56: 463-469.
192. Ooi TC, Raymond A, Cousins M, et al. Relationship between testosterone, estradiol and circulating PCSK9: Cross-sectional and interventional studies in humans. *Clinica chimica acta; international journal of clinical chemistry* 2015; 446: 97-104.
193. Persson L, Cao G, Stahle L, et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. *Arterioscler Thromb Vasc Biol* 2010; 30: 2666-2672.
194. Awan Z, Dubuc G, Faraj M, et al. The effect of insulin on circulating PCSK9 in postmenopausal obese women. *Clinical biochemistry* 2014; 47: 1033-1039.
195. Costet P, Cariou B, Lambert G, et al. Staels, and M. Krempf. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. *The J Bio Chem* 2006; 281: 6211-6218.
196. Miao J, Manthena PV, Haas ME, et al. Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9. *Arterioscler Thromb Vasc Biol* 2015; 35: 1589-1596.
197. Persson L, Galman C, Angelin B, et al. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. *Endocrinology* 2009; 150: 1140-1146.
198. Levy E, Lalonde G, Delvin M. et al. Intestinal and hepatic cholesterol carriers in diabetic *Psammomys obesus*. *Endocrinology* 2010; 151: 958-970.
199. Dube E, Ethier-Chiasson M, Lafond J. Modulation of cholesterol transport by insulin-treated gestational diabetes mellitus in human full-term placenta. *Biology of reproduction* 2013; 88: 16.
200. Bonde Y, Breuer O, Lutjohann D, et al. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. *J Lipid Res* 2014; 55: 2408-2415.
201. Pearce EN. Update in lipid alterations in subclinical hypothyroidism. *The Journal of clinical endocrinology and metabolism* 2012; 97: 326-333.
202. Kwakernaak AJ, Lambert G, Slagman MC, et al. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment. *Atherosclerosis* 2013; 226: 459-465.
203. Guo W, Fu J, Chen X, et al. The effects of estrogen on serum level and hepatocyte expression of PCSK9. *Metabolism* 2015; 64: 554-560.
204. Contreras-Jurado, C, Pascual A. Thyroid hormone regulation of APP [beta-amyloid precursor protein] gene expression in brain and brain cultured cells. *Neurochem Int* 2012; 60: 484-487.
205. O'Barr SA, Oh JS, Ma C, et al. Thyroid hormone regulates endogenous amyloid-beta precursor protein gene expression and processing in both in vitro and in vivo models. *Thyroid* 2006; 16: 1207-1213.
206. Liu F, Gong CX. Tau exon 10 alternative splicing and tauopathies. *Mol Neurodegener* 2008; 3: 8.
207. Roberts CG, Ladenson PW. Hypothyroidism. *Lancet* 2004; 363: 793-803.
208. Rousselet E, Marcinkiewicz J, Kriz J, et al. PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. *J Lipid Res* 2011; 52: 1383-1391.
209. Bingham B, Shen R, Kotnis S, et al. Proapoptotic effects of NARC 1 [= PCSK9], the gene encoding a novel serine proteinase. *Cytometry A* 2006; 69: 1123-1131.
210. Poirier S, Prat A, Marcinkiewicz E, et al. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. *J Neurochem* 2006; 98: 838-850.
211. West R, Beerli MS, Schmeidler J, et al. Better memory functioning associated with higher total and low-density lipoprotein cholesterol levels in very elderly subjects without the apolipoprotein e4 allele. *Am J Geriatr Psychiatry* 2008; 16: 781-785.
212. Sirois F, Gbeha E, Sanni A, et al. Ethnic differences in the frequency of the cardioprotective C679X PCSK9 mutation in a West African population. *Genet Test* 2008; 12: 377-380.
213. Karasinska JM, Rinninger F, Lutjohann D, et al. Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. *J Neurosci* 2009; 29: 3579-3589.
214. Siegelv G, Mockenhaupt FHME, Behnke AL, et al. Lipoprotein binding to anionic biopolyelectrolytes and the effect of glucose on nanoplaque formation in arteriosclerosis and Alzheimer's disease. *Advances in Colloid and Interface Science* 2016; 232: 25-35

Citation: Oldham CE, Powell RS, Williams AB, et al. Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease. *Int J Biomed Investig* 2018; 1: 106.

This manuscript was peer-reviewed

Mode of Review: Single-blinded

Academic Editor: Dr. Li Pin Kao

Copyright: ©2018 Oldham CE, et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License [<http://creativecommons.org/licenses/by/4.0/>], which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author[s] and the source, provide a link to the Creative Commons license, and indicate if changes were made.

